What is the Bristol-Myers Squibb Company stock price forecast?

Bristol-Myers Squibb Company is currently trading at $57.13. View real-time AI analysis on Alpha Lenz.

What is Bristol-Myers Squibb Company insider trading activity?

View the latest insider trading data for Bristol-Myers Squibb Company on Alpha Lenz.

What is Bristol-Myers Squibb Company's P/E ratio?

Bristol-Myers Squibb Company's P/E ratio is 16.5.

Bristol-Myers Squibb Company

NYSE · BMY

$57.13+0.23(+0.40%)Pre-market

Ask about Bristol-Myers Squibb Company's future dividend policy...

Alpha Chat Insight

“Bristol-Myers Squibb Company trades at a P/E of 16.5 (fair value) with strong ROE of 40.5%. Operating margin of 28.5% indicates strong profitability.”

Ask for details →

Company Overview

Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.

CEODr. Christopher S. Boerner Ph.D.

Websitehttps://www.bms.com

SectorHealthcare

IndustryDrug Manufacturers - General

Employees34,100

Company Statistics

FY 2025

Profile

$116.20BMarket Cap

$48.20BRevenue

0.00Shares Out

34,100Employees

Margins

71.08%Gross

41.38%EBITDA

28.48%Operating

19.35%Pre-Tax

14.64%Net

Valuation

16.48P/E

6.29P/B

2.41EV/Sales

7.68EV/EBITDA

9.05P/FCF

Growth (CAGR)

1.45%Rev 3Yr

2.54%Rev 5Yr

14.66%Op Inc 3Yr

44.52%Op Inc 5Yr

3.60%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

7.73%ROA

40.53%ROE

12.29%ROIC

Financial Health

$10.21BCash & Cash Equivalents

$61.32BNet Debt

386.53%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Bristol-Myers Squibb Company trades at a P/E of 16.5 (fair value) with strong ROE of 40.5%. Operating margin of 28.5% indicates strong profitability.”

Ask for details →

Frequently Asked Questions

Bristol-Myers Squibb Company (ticker: BMY) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - General). It has approximately 34,100 employees. Market cap is $116.2B.

The current price is $57.13 with a P/E ratio of 16.48x and P/B of 6.29x.

ROE is 40.53% and operating margin is 28.48%. Annual revenue is $48.2B.